The State of Metabolic Health in America, 2026 Baseline Edition · James M. Knox · DOI: 10.5281/zenodo.22772957 · Last reviewed: October 2026

All Figures

The State of Metabolic Health in America, 2026 Baseline Edition

28 figures · Chapters 1–10

Chapter 1 — The Metabolic Health Landscape

Figure 1-1Adult Obesity and Severe Obesity Trend, 1960–1962 to August 2021–August 2023
Figure 1-1. Adult Obesity and Severe Obesity Trend, 1960–1962 to August 2021–August 2023
Long-run trend in adult obesity and severe obesity prevalence in the United States, showing sustained increases across six decades.
Figure 1-2Diabetes and Prediabetes Composition of the U.S. Adult Population
Figure 1-2. Diabetes and Prediabetes Composition of the U.S. Adult Population
Breakdown of diagnosed diabetes, undiagnosed diabetes, and prediabetes as shares of the U.S. adult population.
Figure 1-3Hypertension Prevalence by Age Group
Figure 1-3. Hypertension Prevalence by Age Group
Hypertension prevalence rises sharply with age, with rates exceeding 70% among adults 65 and older.
Figure 1-4The CKD Awareness Gap
Figure 1-4. The CKD Awareness Gap
Most adults with chronic kidney disease are unaware of their diagnosis, creating a substantial gap between prevalence and diagnosed cases.
Figure 1-5MASLD Prevalence Range and Diabetes Overlap
Figure 1-5. MASLD Prevalence Range and Diabetes Overlap
Metabolic dysfunction-associated steatotic liver disease prevalence estimates and its overlap with the diabetes population.
Figure 1-6The Sleep Apnea Diagnosis Gap
Figure 1-6. The Sleep Apnea Diagnosis Gap
A large share of adults with obstructive sleep apnea remain undiagnosed, limiting treatment and metabolic health management.
Figure 1-7Leading Causes of Death and the CVD Share, 2023
Figure 1-7. Leading Causes of Death and the CVD Share, 2023
Cardiovascular disease remains the leading cause of death in the United States, accounting for a disproportionate share of total mortality.
Figure 1-8Metabolic Syndrome Prevalence Over Time
Figure 1-8. Metabolic Syndrome Prevalence Over Time
Metabolic syndrome prevalence has increased over successive NHANES survey periods, reflecting worsening cardiometabolic risk across the population.
Figure 1-9Testosterone Deficiency Prevalence by Population
Figure 1-9. Testosterone Deficiency Prevalence by Population
Testosterone deficiency rates vary substantially by population subgroup and are closely linked to metabolic health status.
Figure 1-10Menopause Symptom Prevalence and Duration
Figure 1-10. Menopause Symptom Prevalence and Duration
Prevalence and typical duration of menopause-related symptoms, which intersect with metabolic health trajectories in midlife women.

Chapter 2 — The Economic Burden

Figure 2-1National Health Expenditures as a Share of GDP, 2014–2033
Figure 2-1. National Health Expenditures as a Share of GDP, 2014–2033
U.S. health spending as a percentage of GDP, with projections through 2033 showing continued growth driven in part by metabolic disease.
Figure 2-2Obesity and Diabetes Spending Over Time
Figure 2-2. Obesity and Diabetes Spending Over Time
Direct medical spending attributable to obesity and diabetes has grown substantially, outpacing overall health expenditure growth.
Figure 2-3Employer-Sponsored Family Premium Growth, 2015–2025
Figure 2-3. Employer-Sponsored Family Premium Growth, 2015–2025
Employer-sponsored family health insurance premiums have grown significantly over the past decade, driven partly by metabolic disease costs.
Figure 2-4The Composition of Lost Productivity
Figure 2-4. The Composition of Lost Productivity
Breakdown of productivity losses attributable to poor metabolic health, including absenteeism, presenteeism, and disability.
Figure 2-5Obesity-Attributable Job Absenteeism in the United States
Figure 2-5. Obesity-Attributable Job Absenteeism in the United States
Estimated days of work lost annually due to obesity-related illness, representing a significant but often overlooked employer cost.
Figure 2-6International Evidence on Metabolic Health and Disability Pension Risk
Figure 2-6. International Evidence on Metabolic Health and Disability Pension Risk
Cross-national evidence linking poor metabolic health to elevated disability pension risk, with implications for workforce participation.
Figure 2-7Every Dollar of Poor Health
Figure 2-7. Every Dollar of Poor Health
A comprehensive accounting of the full economic cost of poor metabolic health, spanning direct medical, productivity, and societal costs.

Chapter 3 — Employer Health Benefits

Figure 3-1GLP-1 Coverage Continuation Intent for 2027
Figure 3-1. GLP-1 Coverage Continuation Intent for 2027
Survey of employer plan sponsors on their intent to continue or expand GLP-1 medication coverage in 2027 benefit designs.

Chapter 4 — Medicare

Figure 4-1The Medicare Eligibility Cliff in GLP-1 Access
Figure 4-1. The Medicare Eligibility Cliff in GLP-1 Access
The transition to Medicare creates an abrupt change in GLP-1 coverage access for many beneficiaries, creating a coverage cliff.
Figure 4-2Medicare Advantage Supplemental Benefit Availability, Individual Plans vs. Special Needs Plans
Figure 4-2. Medicare Advantage Supplemental Benefit Availability, Individual Plans vs. Special Needs Plans
Comparison of supplemental benefit availability in standard Medicare Advantage plans versus Special Needs Plans for metabolic health services.
Figure 4-3The Medicare Diabetes Prevention Program Utilization Gap
Figure 4-3. The Medicare Diabetes Prevention Program Utilization Gap
Despite broad eligibility, utilization of the Medicare Diabetes Prevention Program remains far below its potential reach.
Figure 4-4The Redesigned Part D Benefit: Winners and Trade-offs
Figure 4-4. The Redesigned Part D Benefit: Winners and Trade-offs
Analysis of the restructured Medicare Part D benefit design and its differential effects on beneficiaries with metabolic conditions.

Chapter 5 — Medicaid

Figure 5-1Medicaid Policy and Enrollment, 2020–2027
Figure 5-1. Medicaid Policy and Enrollment, 2020–2027
Medicaid enrollment trends and key policy changes from 2020 through 2027, including the unwinding of continuous enrollment protections.

Chapter 6 — Public Health Infrastructure

Figure 6-1The Public Health Funding and Surveillance Chain
Figure 6-1. The Public Health Funding and Surveillance Chain
The interconnected chain of federal, state, and local public health funding and surveillance systems that track metabolic health.

Chapter 8 — Medicaid Innovation

Figure 8-1The Medicaid Innovation Framework
Figure 8-1. The Medicaid Innovation Framework
A framework for categorizing Medicaid innovation initiatives by intervention type and outcome domain for metabolic health.
Figure 8-2Medicaid Innovation Chronology, 2017–2026
Figure 8-2. Medicaid Innovation Chronology, 2017–2026
Timeline of major Medicaid innovation milestones from 2017 through 2026, including DSRIP programs and Section 1115 demonstrations.
Figure 8-3North Carolina Healthy Opportunities Pilots: Authorization, Operation, and Outcomes
Figure 8-3. North Carolina Healthy Opportunities Pilots: Authorization, Operation, and Outcomes
Overview of the North Carolina Healthy Opportunities Pilots program, its authorization, operational scope, and health outcome results.

Chapter 9 — Medicare Innovation

Figure 9-3The ACCESS Model's Cardio-Kidney-Metabolic Tracks
Figure 9-3. The ACCESS Model's Cardio-Kidney-Metabolic Tracks
Structure of the CMS ACCESS model's cardio-kidney-metabolic payment tracks, launched July 2026 and running ten years.
Figures reproduced from The State of Metabolic Health in America, 2026 Baseline Edition. Licensed under CC BY 4.0. Full source citations and methodology notes are available in the complete PDF report.

How to cite this page

Knox, J. M. (2026). The State of Metabolic Health in America, 2026 Baseline Edition: Annual Policy Report. Zenodo. https://doi.org/10.5281/zenodo.22772957

© 2026 James M. Knox. Figures may be reproduced with attribution: Knox, J. M. (2026). The State of Metabolic Health in America, 2026 Baseline Edition: Annual Policy Report. Zenodo. https://doi.org/10.5281/zenodo.22772957 ISSN 3144-8178 (Online)